Tekstin koko

11. Loppusanat ja viitteet

Kaiken kaikkiaan Parkinsonin taudin historia on monivivahteinen ja osoittaa, että monet asiat keksitään ”uudelleen” vuosien kuluessa. Sekä potilaat että hoitavat lääkärit odottavat sitä historiallista päivää, kun joku keksii tähän tautiin parantavan tai edes taudin etenemistä estävän hoidon.

  Viitteet

1. Gourie-Devi M, Ramu MG, Venkataram BS. Treatment of Parkinson's disease in 'Ayurveda' (ancient Indian system of medicine): discussion paper. J R Soc Med 1991, 84: 491-2.
2. Manyam BV. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov Disord 1990, 5: 47-8.
3. Zhang ZX, Dong ZH, Roman GC. Early descriptions of Parkinson disease in ancient China. Arch Neurol 2006, 63: 782-4.
4. Zheng GQ. Therapeutic history of Parkinson's disease in Chinese medical treatises. J Altern Complement Med 2009, 15: 1223-30.
5. Koehler PJ, Keyser A. Tremor in Latin texts of Dutch physicians: 16th-18th centuries. Mov Disord 1997, 12: 798-806.
6. Calne DB, Dubini A, Stern G. Did Leonardo describe Parkinson's disease? N Engl J Med 1989, 320: 594.
7. Bereczki D. The description of all four cardinal signs of Parkinson's disease in a Hungarian medical text published in 1690. Parkinsonism Relat Disord 2009.
8. Stern G. Did parkinsonism occur before 1817? J Neurol Neurosurg Psychiatry 1989, Suppl: 11-2.
9. Parkinson J. An Essay on the Shaking Palsy. 1817, London: Sherwood, Neely & Jones.
10. Pearce JM. Aspects of the history of Parkinson's disease. J Neurol Neurosurg Psychiatry 1989, Suppl: 6-10.
11. Goetz CG. Charcot on Parkinson's disease. Mov Disord 1986, 1: 27-32.
12. Lees AJ, Selikhova M, Andrade LA, Duyckaerts C. The black stuff and Konstantin Nikolaevich Tretiakoff. Mov Disord 2008, 23: 777-83.
13. Holdorff B. Friedrich Heinrich Lewy (1885-1950) and his work. J Hist Neurosci 2002, 11: 19-28.
14. Relander K. Patognomisia silmäänpistäviä tunnusmerkkejä muutamissa hermotaudeissa. Duodecim 1890, 10: 165-70.
15. Krusz JC, Koller WC, Ziegler DK. Historical review: abnormal movements associated with epidemic encephalitis lethargica. Mov Disord 1987, 2: 137-41.
16. Lunsford LD. Lars Leksell. Notes at the side of a raconteur. Stereotact Funct Neurosurg 1996, 67: 153-68.
17. Laitinen LV. Personal memories of the history of stereotactic neurosurgery. Neurosurgery 2004, 55: 1420-8; discussion 8-9.
18. Quinn NP. Anti-parkinsonian drugs today. Drugs 1984, 28: 236-62.
19. Talanti S. Parkinsonin tauti. Duodecim 1963, 79: 570-8.
20. Barcroft H, Schwab RS. The effect of apomorphine and that of adrenalin, on the tremor of Parkinson's disease. J Nerv Ment Dis 1951, 114: 541-2.
21. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180: 1200.
22. Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958, 127: 471.
23. Carlsson A. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 2002, 109: 777-87.
24. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidalen Systems. Klin Wochenschr 1960, 38: 1236-9.
25. Birkmayer W, Hornykiewicz O. Der l-Dioxyphenylalanin (l-Dopa)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961, 73: 787-8.
26. Sano H. Biochemistry of the extrapyramidal system Shinkei Kennkyu No Shinpo, Advances in Neurological Sciences. Tokyo, October 1960;5:42-48. Parkinsonism Relat Disord 2000, 6: 3-6.
27. Roe DL. From DOPA to Parkinson's disease: the early history of dopamine research. J Hist Neurosci 1997, 6: 291-301.
28. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 2002, 23: 65-70.
29. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008, 23 Suppl 3: S497-508.
30. Guggenheim M. Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba. Hoppe-Seyler's Z Physiol Chem 1913, 88: 276-84.
31. Rinne UK, Sonninen V. A double blind study of l-dopa treatment in Parkinson's disease. Eur Neurol 1968, 1: 180-91.
32. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967, 276: 374-9.
33. Cotzias GC. L-Dopa for Parkinsonism. N Engl J Med 1968, 278: 630.
34. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969, 21: 343-54.
35. Kivalo E, Boman K, Meurman T, Porras J, Somer H, Taalas J. L-dopa-hoito parkinsonismissa. Suomen Lääkäril 1969, 24: 3198-202.
36. Rinne UK, Sonninen V, Siirtola T. Levodopahoito Parkinsonin taudissa. Duodecim 1971, 87: 933-47.
37. Schwab RS, England AC, Jr., Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969, 208: 1168-70.
38. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976, 11: 329-77.
39. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979, 277: 93-6.
40. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in Parkinsonism. Br Med J 1974, 4: 442-4.
41. Saarinen A, Myllylä V, Reunanen M, Hokkanen E. Bromokriptiini. Duodecim 1977, 93: 1219-26.
42. Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 2004, 111: 1375-446.
43. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979, 1: 249-54.
44. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219: 979-80.
45. Knoll J. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view. Pharmacol Toxicol 1992, 70: 317-21.
46. Oldfield V, Keating GM, Perry CM. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs 2007, 67: 1725-47.
47. Marttila R, Heikkinen E, Hänninen J, Jousilahti P, Jäättelä A, Kaakkola S, Keränen T, Sotaniemi K, Teräväinen H. Parkinsonin tauti. Duodecim 2006, 122: 2655-6.
48. Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999, 51: 593-628.
49. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000, 59: 1233-50.
50. Teräväinen H. Entakaponi Parkinsonin taudin hoidossa. Duodecim 1999, 115: 2734-44.
51. Rinne UK, Ruottinen HM, Gordin A. COMT-eston asema Parkinsonin taudin lääkehoidossa. Suomen Lääkäril 2000, 55: 189-96.
52. Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 2005, 19: 165-84.
53. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992, 76: 53-61.
54. Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P. Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord 1998, 13 Suppl 3: 119-25.
55. Heikkinen E, Erola T, Tuominen J, Juolasmaa A, Haapaniemi T, Myllylä V. Parkinsonin taudin sähköstimulaatiohoito. Duodecim 2004, 120: 789-96.
56. Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med 1987, 316: 831-4.
57. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996, 19: 102-9.
58. Lindvall O. Stem cells for cell therapy in Parkinson's disease. Pharmacol Res 2003, 47: 279-87.
59. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344: 710-9.
60. Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003, 54: 403-14.
61. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Clin Pharmacokinet 2006, 45: 109-36.
62. Pekkonen E. Levodopainfuusio ja apomorfiini Parkinsonin taudin hoidossa. Duodecim 2008, 124: 402-9.
63. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9: 589-95.
64. Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59: 459-66.
65. Marks WJ Jr, Bartus RT, Siffert J et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9: 1164-72
66. Lindholm D, Mäkelä J, Di Liberto V et al. Current disease modifying approaches to treat Parkinson's disease. Cell Mol Life Sci 2016, 73: 1365-79.
67. Rodrigues FB, Ferreira JJ. Opicapone for the treatment of Parkinson's disease. Expert Opin Pharmacother 2017, 18: 445-453.
68. Blair HA, Dhillon S. Safinamide: A Review in Parkinson's Disease. CNS Drugs 2017, 31: 169-176.

 

Kirjoittaja:
Prof. Seppo Kaakkola